Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Orally Available Drug Candidates for Acute Myeloid Leukemia
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Xuejiao Shirley Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Texas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is the second most prevalent and fatal form of leukemia. The growth of AML cells harboring oncogenic MLL rearrangements relies on the YEATS domain-containing protein ENL. Many small molecule inhibitors targeting ENL have been developed. To prioritize these inhibitors for in vivo studies, a NanoBRET system was introduced to evaluate their cellular permeability and potency. This screening identified inhibitor 13 as a promising candidate. This inhibitor has remarkable metabolic stability and potent antiproliferative effects on MLL-fusion leukemia cell lines. In AML-xenografted mice, inhibitor 13 significantly improved survival. Subsequent optimization efforts led to the development of SR-C-107 (R), which exhibited strong activity against AML both at the cellular level (CC50 (MOLM-13): 1.25 ± 0.18 μM; CC50 (MV4-11): 0.81 ± 0.15 μM) and in vivo. These findings establish SR-C-107 (R) as a compelling candidate for AML treatment and lay the groundwork for the development of next-generation AML inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Texas A&M Drug Discovery Center and Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.
- Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University, College Station, Texas 77843, United States.
- Institute of Biosciences and Technology and Department of Translational Medical Sciences, College of Medicine, Texas A&M University, Houston, Texas 77030, United States.
- Department of Biochemistry and Biophysics, Texas A&M University, College Station, Texas 77843, United States.
- Department of Cell Biology and Genetics, College of Medicine, Texas A&M University, Bryan, Texas 77807, United States.
ORCID-Profile: Peng-Hsun Chase Chen, Shiqing Xu, Wenshe Ray Liu
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- National Cancer Institute
- Welch Foundation
- Division of Cancer Prevention, National Cancer Institute
- Cancer Prevention and Research Institute of Texas
- National Institute of General Medical Sciences
Zitieren
APA
Guo, X. S., Atla, S., Nyalata, S., Alugubelli, Y. R., Chen, P. C., Xu, S., & Liu, W. R. (2024). Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Orally Available Drug Candidates for Acute Myeloid Leukemia. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01337
Vancouver
Guo XS, Atla S, Nyalata S, Alugubelli YR, Chen PC, Xu S, et al. Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Orally Available Drug Candidates for Acute Myeloid Leukemia. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01337
BibTeX
@article{Guo2024,
author = {Guo, Xuejiao Shirley and Atla, Sandeep and Nyalata, Satyanarayana and Alugubelli, Yugendar R and Chen, Peng-Hsun Chase and Xu, Shiqing and Liu, Wenshe Ray},
title = {Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Orally Available Drug Candidates for Acute Myeloid Leukemia},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01337}
}
EUVIMED